IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, October 2022

An Overview on Hypertension in Pregnancy

Dr Astha Lalwani, Professor,
Department of Obst. & Gynae, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
Email Id- asthalalwanirastogi@gmail.ocm

ABSTRACT: ***The most frequent medical condition seen during pregnancy is hypertension. In the United States, hypertensive disorders are one of the leading causes of maternal mortality during pregnancy. A thorough review of the literature on hypertension in pregnancy will be presented. The first section of the article defines and categorizes hypertensive diseases in pregnancy. The physiological changes in the vascular or renal systems that occur during pregnancy are described in depth. We will review the fascinating elements of preeclampsia pathophysiology, with a focus on current developments in the area. The current diagnostic techniques as well as the tests that have been suggested for preeclampsia screening are thoroughly discussed. And also discuss preeclampsia's short- and long-term consequences. Finally, we go through current management recommendations, treatment objectives, and the possible risks and advantages of different antihypertensive medication groups. Preeclampsia is still a mystery, and current care relies on the monitoring and treatment of its symptoms. We hope that this in-depth analysis will spur new research in the area and help practitioners better identify women at risk and treat them.***

KEYWORDS: ***Blood Pressure, Hypertension, Pregnancy, Physiology.***

1. INTRODUCTION

Hypertension is the most prevalent medical condition of pregnancy, affecting an estimated 240,000 women in the United States each year and complicating up to 1 in 10 pregnancies. Although preeclampsia has been recognized by doctors for millennia, little is known about its etiology and prevention. The main worry with high blood pressure is the potential for damage to both the mother and the fetus. The severity of these possible side effects ranges from minor to life-threatening.

1.1.Hypertensive Disorders of Pregnancy: Classification:

The National Heart, Lung, and Blood Institute's National High Blood Pressure Education Program divides hypertensive diseases of pregnancy into four categories: gestational hypertension, chronic hypertension, preeclampsia, and preeclampsia with preexisting hypertension. In pregnancy, hypertension is defined as a systolic pressure of 140 mm Hg or a diastolic pressure of 90 mm Hg or higher. Using the patient sitting, blood pressure should be measured in the upper arm with an adequately sized cuff. For at least several minutes, the patient should be at rest. A second blood pressure measurement should be taken at least twenty minutes later, if not on a different occasion. The absence of sound, not the shift in noises, determines the diastolic measurement[1]. The blood pressure parameters used to diagnose preeclampsia are still up for debate. Some specialists in this field have suggested that a fast increase in blood pressure of 30 mm Hg systolic or 15 mm Hg diastolic should be enough to diagnose preeclampsia. However, according to the current guidelines of the 2000 working group, women who have just experienced this shift are not yet preeclamptic, although they should be closely monitored, particularly if proteinuria and hyperuricemia are present[2], [3].

1.2. Normal Pregnancy Vascular Physiology:

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, October 2022

During pregnancy, systemic hemodynamics undergo significant alterations. When attempting to measure blood pressure during pregnancy, it is critical to recognize the changes from the nonpregnant condition. Mean arterial pressure falls throughout an uncomplicated pregnancy, reaching a trough between the 16th and 20th weeks of pregnancy. The drop in diastolic pressure is a little faster than the drop in systolic pressure. The drop in blood pressure is usually 8–10 mm Hg, or less than 10% of pre-pregnancy values. Blood pressure drops during the luteal phase of menstruation and continues to drop if pregnancy occurs. At about 40 weeks gestation, mean arterial blood pressure progressively recovers to pre-pregnancy values after the 20th week. Ambulatory blood pressure monitoring has shown that the circadian variations in blood pressure are maintained throughout pregnancy.

During pregnancy, the levels of hormones that assist control blood volume, such as the components of the renin-angiotensin-aldosterone system and catecholamines, are paradoxically elevated. A decrease in plasma volume or decreased renal perfusion are the most common physiologic triggers for the production of these hormones. Nonetheless, increased renin-angiotensin axis activity is a characteristic of the volume-expanded condition of pregnancy. As a result, pregnancy has been labeled as a condition of "decreased effective plasma volume." Increases in arterial compliance as well as venous capacitance seem to be at the root of this strange physiologic phenomena, whose explanation remains a mystery. The particular type of hypertension in pregnancy known as preeclampsia is characterized by a reversal of this trend, as will be described later. The changes in vascular reactivity are not confined to endogenous hormone responses. Infused pressor chemicals' vasoconstrictive action is also significantly reduced. More than 40 years ago, it was discovered that pregnant women are resistant to the pressor effects of angiotensin II and norepinephrine during pregnancy. Following that, Gant and colleagues discovered a gradual increase in angiotensin II resistance as pregnancy proceeded, peaking between 24 and 30 weeks of pregnancy[4].

1.2.1. In a Normal Pregnancy, the Kidney:

Glomerular hyperfiltration is seen in healthy pregnant women. During human investigations, the fast increase in renal blood flow as well as glomerular filtration rate was observed. GFR starts to rise in the first trimester of pregnancy and peaks in the second half of pregnancy, when it is 40–60 percent higher than nongravid levels. These improvements in renal hemodynamics occurred even before increases in cardiac output and plasma volume, according to Davison and his colleagues. This indicates that the processes behind these significant physiologic changes may be distinct or at the very least unrelated. There is no other case in biology when a person's function improves with time. Because of the enormity of the change, many researchers have attempted to identify the mechanism that underpins it in the hopes of using it to treat other human diseases. So yet, no conclusive explanation has been found. Pregnant individuals with underlying renal illness generally have an increase in function proportionate to their baseline level if the pregnancy is straightforward. The physiologic alteration is most likely teleological, intended to handle the extra waste products produced by the expanding uterus, placenta, and baby. A significant rise in both glomerular filtration rate and renal plasma flow is maintained throughout the pregnancy, but it tends to taper down near the end [5], [6].

1.2.3. Preeclampsia: Volume or Hemodynamic Changes:

It's difficult to research preeclampsia that hasn't been treated, because preeclampsia is often identified in individuals with underlying chronic medical problems. Preeclamptic individuals

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, October 2022

who have been treated or who have underlying renal illness, diabetes, or hypertension may not have data that properly represent the simple preeclamptic patient. Putting these issues aside, the existing evidence indicates that systemic hemodynamic preeclamptics differ significantly from women who are pregnant without complications. Visser and Wallenburg examined the hemodynamics of untreated primiparous preeclamptics in great detail. When comparing these carefully chosen women with pregnancy-induced hypertension to normal control pregnant individuals, they consistently observed lower cardiac outputs and intravascular volumes, as well as greater systemic vascular resistance and cardiac afterload, using Swan-Ganz catheters [7], [8].

1.2.4. Preeclampsia Causes Renal Changes:

In women who develop preeclampsia, the significant increase in renal function that occurs during a normal pregnancy is lost. GFR and renal blood flow both decrease. The degree of the decrease varies widely and is related to the illness's overall severity. If proteinuria develops, as it almost always does, a kidney biopsy will most likely reveal glomerular endotheliosis. Although not specific to pregnancy, this lesion is common in preeclamptic women. This endothelial anomaly is in line with the idea that endothelial damage is a major factor in the pathogenesis of this systemic disease, with the kidney not being spared. These hemodynamic and endothelial alterations seem to render the kidneys more susceptible to acute renal failure (acute tubular necrosis) and, less frequently, renal cortical necrosis, a kind of rapid, often irreversible renal failure. Cortical necrosis is nearly often associated with severe preeclampsia and very rarely occurs outside of pregnancy.

1.3. Pregnancy and Relaxin

Relaxin, a peptide hormone produced by the corpus luteum, circulates in humans, nonhuman primates, rats, as well as mice during pregnancy. In both humans and nonhuman primates, the hormonal is detectable in the blood during the luteal phase of the menstrual cycle. Relaxin has traditionally been studied in the setting of the reproductive tract. The vasodilatory effect of relaxing in non-pregnant rats was shown to be similar to that of pregnancy. Furthermore, during midterm pregnancy in rats, immunoneutralization of relaxin or its removal from the circulation inhibits maternal systemic and renal vasodilation, as well as a rise in global arterial compliance.

1.3.3. Preeclampsia and Renin-Angiotensin Signaling:

During an uncomplicated pregnancy, virtually all components of the renin angiotensin system rise, while renin activity, angiotensin II, and aldosterone decrease in preeclampsia for unknown reasons. Angiotensin II type 1 receptor agonistic antibody (AT1-AA) has been identified in the blood of preeclamptic women in many investigations. Many recent studies have shown that autoantibodies can increase certain factors (such as sFlt1, sEng, Plasminogen activator inhibitor-1, reactive oxygen species, tissue factor, and NADPH oxidase) that lead to preeclamptic pathophysiology like endothelial cell dysfunction and vascular damage by activating AT1 receptors on a variety of cell types.

1.4. The Importance of Immune System Changes:

Significant progress has been made in understanding the involvement of immunological systems in the development of preeclampsia during the past 30 years. Why primiparous women are more vulnerable to this disease, as well as why the high preeclampsia attack rate (5–7%) seen in primiparous women is unaltered in women who are having their first pregnancy with a second partner, remains unknown. This has led to the theory that the immunologic difference between

the partners, which is entrenched in the fetus, causes an immunological reaction in the pregnant woman. Preeclampsia, according to Redman et al., is the continuation of immune-mediated inflammatory alterations observed in normal pregnancy [9].

1.5. Genetics' Role in Preeclampsia:

Although there are both biological and environmental risk factors for preeclampsia, the presence of preeclampsia in first degree relatives raises a woman's risk of preeclampsia by 2 to 4 times. Genetic factors may play a role in the angiogenic imbalance seen in preeclampsia patients. Several sFlt1 and VEGF polymorphisms have recently been linked to the severity of preeclampsia. Despite the fact that circulating PGF, sFlt1, and sEng levels have been proven to be significant indicators of preeclampsia, no causative mutations in these genes have been linked to preeclampsia. Preeclampsia is more common in mothers who have trisomy 13 fetuses, indicating that gene dosage or copy number variation may play a role in the development of preeclampsia. The Flt1 gene, for example, is found on chromosome.

1.5.1. Hypertension in Pregnancy and Its Consequences:

In the United States, hypertension during pregnancy is a leading cause of maternal morbidity and death. Preeclampsia eclampsia causes around one maternal death per 100,000 live births, with a case-fatality rate of 6.4 fatalities per 10,000 cases. Multiple variables influence the outcome of hypertension in pregnancy, which is unsurprising. These factors include (but are not limited to) gestational age at illness start, disease severity, and the existence of concomitant diseases such as diabetes, renal disease, thrombophilia, or preexisting hypertension. Short-term and long-term problems associated with hypertension in pregnancy may be distinguished. Short-term problems are divided into maternal and fetal complications, while long-term consequences are mostly maternal.

1.6. Hypertension Treatment:

The first step in treating hypertension during pregnancy is to accurately identify the type and severity of the condition. The aforementioned limited benefit of trying to fully regulate blood pressure in this situation is implicit in this guidance. The second, and probably more essential, concept is to recognize the fetus's possible susceptibility to therapy. In the United States, the estimated prevalence of chronic hypertension in pregnancy is 3%, and it is on the rise. This rise in prevalence has been linked to rising obesity rates and postponing childbearing until later in life, when chronic hypertension is more prevalent. Despite the increased risk of superimposed preeclampsia in these individuals, many will have a physiological drop in blood pressure throughout pregnancy, reducing the need for any previously prescribed antihypertensive medication. It's fairly uncommon for blood pressure to rebound to the hypertensive range in the third trimester.

1.7.1. Hypertension during pregnancy:

Gestational hypertension is a condition in which a woman's blood pressure rises after 20 weeks of pregnancy in a previously healthy woman, but without proteinuria. It causes complications in 6% of all pregnancies. These women are at a high risk of having preeclampsia, which may strike at any moment throughout pregnancy, including the first week after delivery, and requires careful monitoring. Preeclampsia affects around 15–45 percent of pregnant women. The treatment aim is the same as for chronic hypertension.

1.7.2. Preeclampsia:

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, October 2022

Preeclamptic individuals may benefit from the same basic concepts that govern the management of women with persistent hypertension. While undergoing therapy, it is critical to keep a close eye on the fetus for signs of discomfort. Preeclampsia that develops early (less than 34 weeks) necessitates the use of antihypertensive medicines, bed rest, and in-hospital monitoring of both the mother and the fetus. This method may assist to postpone birth and therefore enhance the fetal fate. These individuals are often intravascularly deficient, making them more vulnerable to drug-induced blood pressure decreases. If there are any additional indications of fetal or maternal distress, delivery is the only option.

1.7. Breastfeeding is a method of nourishing a child:

Nursing exposure to methyldopa is relatively minimal and usually regarded safe for newborns. Breast milk has high amounts of atenolol and metoprolol, which may harm the baby; however, exposure to labetalol and propranolol seems to be minimal. Although diuretics have modest quantities in milk and are generally safe, they may reduce milk supply by causing volume constriction in the mother. Calcium channel blockers have been reported to pass into breast milk, however the relative baby dosage of nifedipine, verapamil, and diltiazem is minimal, and they are all safe to breastfeed. Three ACE inhibitors, captopril, enalapril, and quinapril, have enough evidence to be considered safe while breastfeeding, according to the American Academy of Pediatrics. Because there is presently inadequate evidence on angiotensin II receptor blockers, it is not recommended to take them during breastfeeding [10].

2. DISCUSSION

High blood pressure that develops during pregnancy is known as gestational hypertension. It begins when you have reached the 20-week mark of your pregnancy. There are typically no additional signs or symptoms. It usually causes no damage to you or your baby, and it fades gone within 12 weeks after delivery. However, it increases your chances of developing high blood pressure in the future. It may be severe at times, resulting in low birth weight or premature delivery. Preeclampsia may occur in certain women with gestational hypertension. High blood pressure that began before the 20th week of pregnancy or before you got pregnant is known as chronic hypertension. Some women may have had it for a long time but were unaware of it until their blood pressure was tested at their prenatal appointment. Chronic hypertension may sometimes lead to preeclampsia. Preeclampsia is a condition in which blood pressure rises suddenly after the 20th week of pregnancy. It typically occurs throughout the third trimester. Symptoms may not appear till after birth in certain instances. Postpartum preeclampsia is the medical term for this condition. Some of your organs, such as your liver or kidney, may be damaged as a result of preeclampsia. Protein in the urine and very high blood pressure are two possible symptoms. Both you and your baby are at risk from preeclampsia, which may be fatal.

3. CONCLUSION

During pregnancy, several women have elevated blood pressure. This may put the woman and her unborn child at risk of complications during pregnancy. High blood pressure may create complications during and after childbirth. High blood pressure can be prevented and treated, which is excellent news. Preeclampsia may occur after you've given birth in rare instances. Postpartum preeclampsia is a severe medical disease that occurs after a woman gives birth. It may happen to women who have never had preeclampsia throughout their pregnancy. Postpartum preeclampsia has symptoms that are similar to those of preeclampsia external

symbol. Preeclampsia after birth is usually detected within 48 hours, although it may occur up to 6 weeks later.

REFERNCES:

[1] J. Bauer, "Genetics of essential hypertension: historical perspective and current concept.," *Acta Genet. Med. Gemellol. (Roma).*, 1968, doi: 10.1017/s1120962300012440.

[2] P. Prinja and C. Nelson-Piercy, "Hypertension in pregnancy," *Medicine (United Kingdom)*. 2018, doi: 10.1016/j.mpmed.2018.09.010.

[3] "Hypertension in Pregnancy among Rural Women in Katsina State, Nigeria," *J. Basic Clin. Reprod. Sci.*, 2017.

[4] C. Barlassina, C. Lanzani, P. Manunta, and G. Bianchi, "Genetics of essential hypertension: From families to genes," 2002, doi: 10.1097/01.asn.0000032524.13069.88.

[5] S. Shekhar, N. Gupta, R. Kirubakaran, and P. Pareek, "Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: A systematic review and meta-analysis," *BJOG: An International Journal of Obstetrics and Gynaecology*. 2016, doi: 10.1111/1471-0528.13463.

[6] A. Camussi and G. Bianchi, "Genetics of essential hypertension. From the unimodal-bimodal controversy to molecular technology," *Hypertension*. 1988, doi: 10.1161/01.HYP.12.6.620.

[7] A. Natekar, R. L. Olds, M. W. Lau, K. Min, K. Imoto, and T. P. Slavin, "Elevated blood pressure: Our family's fault? The genetics of essential hypertension," *World J. Cardiol.*, 2014, doi: 10.4330/wjc.v6.i5.327.

[8] *Genetics and Pathophysiology of Essential Hypertension*. 2012.

[9] H. Chen and M. X. Guan, "Mitochondrial genetics and human essential hypertension," *Chinese Journal of Medical Genetics*. 2012, doi: 10.3760/cma.j.issn.1003-9406.2012.03.010.

[10] A. P. Gimenez-Roqueplo and X. Jeunemaitre, "Genetics of Essential Hypertension: Candidate Genes or Screening of the Whole Genome?," *Arch. Mal. Coeur Vaiss.*, 2003.